{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:56:27Z","timestamp":1792403787618,"version":"4.4.0"},"reference-count":116,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>B and T cells collaborate to drive autoimmune disease (AID). Historically, B- and T-cell (B\u2013T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B-cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and organ transplantation benefit from targeted BCD with anti-CD20 monoclonal antibodies such as rituximab, ocrelizumab, or ofatumumab. Refractory AID is a significant problem for patients with incomplete BCD with a greater frequency of IgD\u2212CD27+ switched memory B cells, CD19+CD20\u2212 B cells, and plasma cells that are not directly targeted by anti-CD20 antibodies, whereas most lymphoid tissue plasma cells express CD19. Furthermore, B\u2013T-cell collaboration is predominant in lymphoid tissues and at sites of inflammation such as the joint and kidney, where BCD may be inefficient, due to limited access to key effector cells. In the treatment of cancer, chimeric antigen receptor (CAR) T-cell therapy and T-cell engagers (TCE) that recruit T cells to induce B-cell cytotoxicity have delivered promising results for anti-CD19 CAR T-cell therapies, the CD19 TCE blinatumomab and CD20 TCE such as mosunetuzumab, glofitamab, or epcoritamab. Limited evidence suggests that anti-CD19 CAR T-cell therapy may be effective in managing refractory AID whereas we await evaluation of TCE for use in non-oncological indications. Therefore, here, we discuss the potential mechanistic advantages of novel therapies that rely on T cells as effector cells to disrupt B\u2013T-cell collaboration toward overcoming rituximab-resistant AID.<\/jats:p>","DOI":"10.1093\/cei\/uxae031","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:20:32Z","timestamp":1713658832000},"page":"15-30","source":"Crossref","is-referenced-by-count":44,"title":["Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?"],"prefix":"10.1093","volume":"217","author":[{"given":"Kavina","family":"Shah","sequence":"first","affiliation":[{"name":"Centre for Rheumatology , UCLH , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Leandro","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology , UCLH , London, UK"},{"name":"Department of Rheumatology, University College London Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cragg","sequence":"additional","affiliation":[{"name":"University of Southampton Faculty of Medicine, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton , Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kollert","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Early Development Immunology, Infectious Diseases & Ophthalmology , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Schuler","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Roche Pharma Research and Early Development , Schlieren , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Cancer Immunotherapy Discovery, Oncology Discovery & Translational Area , Schlieren , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-4425","authenticated-orcid":false,"given":"Venkat","family":"Reddy","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology , UCLH , London, UK"},{"name":"Department of Rheumatology, University College London Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"2024062013072836500_CIT0001","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-019-0241-7","article-title":"The rise of peripheral T helper cells in autoimmune disease","volume":"15","author":"Rao","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2024062013072836500_CIT0002","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front Immunol"},{"key":"2024062013072836500_CIT0003","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2018.01941","article-title":"T cell\/B cell collaboration and autoimmunity: an intimate relationship","volume":"9","author":"Petersone","year":"2018","journal-title":"Front Immunol"},{"key":"2024062013072836500_CIT0004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdd.2130","article-title":"Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis","volume":"39","author":"Anil Kumar","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"2024062013072836500_CIT0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland","year":"2020","journal-title":"Am J Transplant"},{"key":"2024062013072836500_CIT0006","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Therapy"},{"key":"2024062013072836500_CIT0007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.31138\/mjr.32.3.192","article-title":"Double negative (DN) B cells: a connecting bridge between rheumatic diseases and COVID-19","volume":"32","author":"Sachinidis","year":"2021","journal-title":"Mediterr J Rheumatol"},{"key":"2024062013072836500_CIT0008","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11926-012-0256-4","article-title":"Belimumab is approved by the FDA: what more do we need to know to optimize decision making","volume":"14","author":"Horowitz","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2024062013072836500_CIT0009","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3390\/jcm12093198","article-title":"Targeted therapy for SLE-what works, what doesn\u2019t, what\u2019s next","volume":"12","author":"Venturelli","year":"2023","journal-title":"J Clin Med"},{"key":"2024062013072836500_CIT0010","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1093\/rheumatology\/keaa796","article-title":"De novo lupus nephritis during treatment with belimumab","volume":"60","author":"Parodis","year":"2020","journal-title":"Rheumatology"},{"key":"2024062013072836500_CIT0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1759720X17690474","article-title":"Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness","volume":"9","author":"Guerreiro Castro","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024062013072836500_CIT0012","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41591-019-0403-9","article-title":"Distinct phenotype of CD4(+) T cells driving celiac disease identified in multiple autoimmune conditions","volume":"25","author":"Christophersen","year":"2019","journal-title":"Nat Med"},{"key":"2024062013072836500_CIT0013","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00125-019-4936-8","article-title":"Circulating CXCR5(-)PD-1(hi) peripheral T helper cells are associated with progression to type 1 diabetes","volume":"62","author":"Ekman","year":"2019","journal-title":"Diabetologia"},{"key":"2024062013072836500_CIT0014","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"2024062013072836500_CIT0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2024062013072836500_CIT0016","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13075-016-1188-6","article-title":"Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies","volume":"18","author":"Cooles","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024062013072836500_CIT0017","article-title":"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor","author":"NICE","year":"2010","journal-title":"Technology Appraisal Guidance [TA195]"},{"key":"2024062013072836500_CIT0018","first-page":"1","article-title":"A phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis","volume":"70","author":"Dooley","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024062013072836500_CIT0019","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024062013072836500_CIT0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/rheumatology\/keab248","article-title":"Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020","volume":"61","author":"Norris-Grey","year":"2021","journal-title":"Rheumatology"},{"key":"2024062013072836500_CIT0021","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheumatism"},{"key":"2024062013072836500_CIT0022","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with Pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"2024062013072836500_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2020.11.002","article-title":"Anti-CD20 monoclonal antibodies in systemic lupus erythematosus","volume":"69","author":"Shah","year":"2021","journal-title":"Biologicals"},{"key":"2024062013072836500_CIT0024","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"2024062013072836500_CIT0025","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024062013072836500_CIT0026","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024062013072836500_CIT0027","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","article-title":"Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer","volume":"21","author":"Reddy","year":"2016","journal-title":"Drug Discov Today"},{"key":"2024062013072836500_CIT0028","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2024062013072836500_CIT0029","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024062013072836500_CIT0030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024062013072836500_CIT0031","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024062013072836500_CIT0032","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2024062013072836500_CIT0033","doi-asserted-by":"crossref","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"2024062013072836500_CIT0034","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"2024062013072836500_CIT0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(\u2212)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"2024062013072836500_CIT0036","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"2024062013072836500_CIT0037","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"2024062013072836500_CIT0038","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024062013072836500_CIT0039","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024062013072836500_CIT0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.56.7.481","article-title":"Pathogenesis of systemic lupus erythematosus","volume":"56","author":"Mok","year":"2003","journal-title":"J Clin Pathol"},{"key":"2024062013072836500_CIT0041","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"2024062013072836500_CIT0042","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/rheumatology\/keab827","article-title":"Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab","volume":"61","author":"Reddy","year":"2021","journal-title":"Rheumatology"},{"key":"2024062013072836500_CIT0043","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"Chang","year":"2011","journal-title":"J Immunol (Baltimore, Md. : 1950)"},{"key":"2024062013072836500_CIT0044","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/cells9122627","article-title":"Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases\u2014implications for therapeutic approaches","volume":"9","author":"Fetter","year":"2020","journal-title":"Cells"},{"key":"2024062013072836500_CIT0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.1373518","article-title":"CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes","volume":"256","author":"Carter","year":"1992","journal-title":"Science"},{"key":"2024062013072836500_CIT0046","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity"},{"key":"2024062013072836500_CIT0047","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa051568","article-title":"An antibody-deficiency syndrome due to mutations in the CD19 gene","volume":"354","author":"van Zelm","year":"2006","journal-title":"N Engl J Med"},{"key":"2024062013072836500_CIT0048","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.immuni.2020.06.013","article-title":"An integrated multi-omic single-cell atlas of human B cell identity","volume":"53","author":"Glass","year":"2020","journal-title":"Immunity"},{"key":"2024062013072836500_CIT0049","doi-asserted-by":"crossref","first-page":"1241474","DOI":"10.3389\/fimmu.2023.1241474","article-title":"Double-negative-2 B cells are the major synovial plasma cell precursor in rheumatoid arthritis","volume":"14","author":"Wing","year":"2023","journal-title":"Front Immunol"},{"key":"2024062013072836500_CIT0050","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2024062013072836500_CIT0051","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"2024062013072836500_CIT0052","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024062013072836500_CIT0053","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.110.168062","article-title":"B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody","volume":"335","author":"Herbst","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"2024062013072836500_CIT0054","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024062013072836500_CIT0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2024062013072836500_CIT0056","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2024062013072836500_CIT0057","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"2024062013072836500_CIT0058","first-page":"166","article-title":"FDA approves fourth CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2024062013072836500_CIT0059","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2024062013072836500_CIT0060","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024062013072836500_CIT0061","first-page":"93","article-title":"OP0141 Long term safety and efficacy of CAR-T cell treatment in refractory systemic lupus erythematosus\u2014data from the first seven patients","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024062013072836500_CIT0062","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024062013072836500_CIT0063","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2024062013072836500_CIT0064","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024062013072836500_CIT0065","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S1525-0016(16)35168-1","article-title":"T cells engineered for resistance to mycophenolate mofetil demonstrate enhanced expansion and improved tumour control in immunosuppressed hosts","volume":"22","author":"Griffin","year":"2014","journal-title":"Mol Ther"},{"key":"2024062013072836500_CIT0066","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2024062013072836500_CIT0067","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024062013072836500_CIT0068","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T\u2014and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"2024062013072836500_CIT0069","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clml.2023.03.002","article-title":"Response to COVID-19 vaccination post-CAR T therapy in patients with non-hodgkin lymphoma and multiple myeloma","volume":"23","author":"Wiedmeier-Nutor","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024062013072836500_CIT0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"2024062013072836500_CIT0071","doi-asserted-by":"crossref","first-page":"e200080","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell\u2013mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"key":"2024062013072836500_CIT0072","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"2024062013072836500_CIT0073","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"key":"2024062013072836500_CIT0074","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"key":"2024062013072836500_CIT0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaccao.2022.09.002","article-title":"Successful CAR T cell therapy in a heart and kidney transplant recipient with refractory PTLD","volume":"4","author":"Oren","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2024062013072836500_CIT0076","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"2024062013072836500_CIT0077","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"2024062013072836500_CIT0078","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"2024062013072836500_CIT0079","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1182\/blood-2019-125286","article-title":"The real life accessibility to CAR T-cell therapy: current experience in the only active center in Italy","volume":"134","author":"Guidetti","year":"2019","journal-title":"Blood"},{"key":"2024062013072836500_CIT0080","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat Commun"},{"key":"2024062013072836500_CIT0081","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2024062013072836500_CIT0082","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/scd.1.1992.1.85","article-title":"Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64\/Fc gamma RI (MoAb 32)","volume":"1","author":"Ball","year":"1992","journal-title":"J Hematother"},{"key":"2024062013072836500_CIT0083","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","article-title":"Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy","volume":"36","author":"Seimetz","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"2024062013072836500_CIT0084","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2024062013072836500_CIT0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2024062013072836500_CIT0086","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"2024062013072836500_CIT0087","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.4049\/jimmunol.152.11.5368","article-title":"Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli","volume":"152","author":"Gruber","year":"1994","journal-title":"J Immunol"},{"key":"2024062013072836500_CIT0088","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng"},{"key":"2024062013072836500_CIT0089","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4161\/mabs.21379","article-title":"Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies","volume":"4","author":"Klein","year":"2012","journal-title":"MAbs"},{"key":"2024062013072836500_CIT0090","doi-asserted-by":"crossref","first-page":"1967714","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"mAbs"},{"key":"2024062013072836500_CIT0091","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"2024062013072836500_CIT0092","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.leukres.2008.08.025","article-title":"Combination of rituximab with blinatumomab (MT103\/MEDI-538), a T cell-engaging CD19-\/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells","volume":"33","author":"d\u2019Argouges","year":"2009","journal-title":"Leuk Res"},{"key":"2024062013072836500_CIT0093","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell\u2013dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"2024062013072836500_CIT0094","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"2024062013072836500_CIT0095","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1158\/1538-7445.AM2017-3629","article-title":"Abstract 3629: Engineering a novel asymmetric head-to-tail 2 + 1 T-cell bispecific (2 + 1 TCB) IgG antibody platform with superior T-cell killing compared to 1 + 1 asymmetric TCBs","volume":"77","author":"Klein","year":"2017","journal-title":"Cancer Res"},{"key":"2024062013072836500_CIT0096","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.285.5425.221","article-title":"The immunological synapse: a molecular machine controlling T cell activation","volume":"285","author":"Grakoui","year":"1999","journal-title":"Science"},{"key":"2024062013072836500_CIT0097","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00007890-197601000-00002","article-title":"Multiple target cell killing by the cytolytic T lymphocyte and the mechanism of cytotoxicity","volume":"21","author":"Martz","year":"1976","journal-title":"Transplantation"},{"key":"2024062013072836500_CIT0098","first-page":"1","article-title":"NICE. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy","year":"2023"},{"key":"2024062013072836500_CIT0099","first-page":"1","article-title":"Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity","volume-title":"Technology appraisal guidance [TA589]","author":"NICE","year":"2019"},{"key":"2024062013072836500_CIT0100","doi-asserted-by":"crossref","first-page":"e0183390","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PLoS One"},{"key":"2024062013072836500_CIT0101","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"key":"2024062013072836500_CIT0102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OARRR.S151013","article-title":"Macrophage activation syndrome: early diagnosis is key","volume":"10","author":"Lerkvaleekul","year":"2018","journal-title":"Open Access Rheumatol"},{"key":"2024062013072836500_CIT0103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomarker Res"},{"key":"2024062013072836500_CIT0104","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"2024062013072836500_CIT0105","doi-asserted-by":"crossref","first-page":"854967","DOI":"10.3389\/fphar.2022.854967","article-title":"PD-1\/PD-L1 Inhibitors in patients with preexisting autoimmune diseases","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024062013072836500_CIT0106","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"2024062013072836500_CIT0107","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"2024062013072836500_CIT0108","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"2024062013072836500_CIT0109","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"2024062013072836500_CIT0110","doi-asserted-by":"crossref","first-page":"e003766","DOI":"10.1136\/jitc-2021-003766","article-title":"JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy","volume":"10","author":"Leclercq","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"2024062013072836500_CIT0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomarker Res"},{"key":"2024062013072836500_CIT0112","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1034\/j.1399-0012.2001.00006.x","article-title":"Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil","volume":"15","author":"Nakamura","year":"2001","journal-title":"Clin Transplant"},{"key":"2024062013072836500_CIT0113","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-3083.1991.tb03747.x","article-title":"Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice","volume":"33","author":"Eugui","year":"1991","journal-title":"Scand J Immunol"},{"key":"2024062013072836500_CIT0114","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.phrs.2011.01.005","article-title":"Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK\/PD relationships","volume":"63","author":"Pr\u00e9maud","year":"2011","journal-title":"Pharmacol Res"},{"key":"2024062013072836500_CIT0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"2024062013072836500_CIT0116","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae031\/57568816\/uxae031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/217\/1\/15\/58288246\/uxae031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/217\/1\/15\/58288246\/uxae031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:08:52Z","timestamp":1718888932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/217\/1\/15\/7655509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,20]]},"published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae031","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,4,20]]}}}